At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 6 enrolled
Drug / intervention
Enstilar Foamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Investigator Initiated Study Evaluating the Efficacy and Tolerability of Enstilar Foam (Calcipotriene and Betamethasone Dipropionate) in Patients With Nail Psoriasis
In Brief
A Phase 4 clinical trial evaluating Enstilar Foam for Nail Psoriasis. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The aim of the study is to evaluate the efficacy and safety of Enstilar Foam (calcipotriene and betamethasone dipropionate) for the treatment of nail psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNail Psoriasis
CountriesUnited States
CollaboratorsLEO Pharma
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartNov 2021
Primary CompletionOct 2023
TodayJul 2026
First PostedJan 13, 2020
Enrollment StartNov 1, 2021
Primary CompletionOct 31, 2023
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 6.5 years ago
Interventions
Enstilar Foamdrug
Subjects will be instructed to apply a thin layer on the nail plate, around the nail plate and under the nail plate. The patient will be instructed to apply one application at night immediately before bed and not wash their hands before morning. All subjects who completed the 6-month treatment will be followed for 1 month after discontinuation.